KAT2B-mediated epigenetic suppression of RAD51C enhances olaparib sensitivity in colorectal cancer
These results offer vital and novel insights into the combination of inhibitors in patients who are resistant to olaparib therapy, especially patients with RAD51C reversion mutations.
Authors
- Xuwei Shen
- Xiaoqin Liu
- Lin Li
- Jun Chen
Institutions
- Xiamen University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Xiamen Chang Gung Hospital (CN)
- Jingning County People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2026-03-14
- DOI
- https://doi.org/10.1007/s00280-026-04872-2
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00